San Antonio Breast Cancer Symposium (SABCS) | December 10 - 14, 2019
San Antonio, TX

  • SM08502, a Novel, Small-Molecule CDC-like Kinase (CLK) Inhibitor, Demonstrates Strong Inhibition of the Wnt Signaling Pathway and Antitumor Effects as Monotherapy and in Combination with Chemotherapy in Triple-Negative Breast Cancer (TNBC) Models
    Abstract - Poster

Cancer Letters | September 24, 2019

  • The CLK inhibitor SM08502 induces anti-tumor activity and reduces Wnt pathway gene expression in gastrointestinal cancer models

    Cancer Letters. doi:10.1016/j.canlet.2019.09.009

    Betty Y.Tam, Kevin Chiu, Heekyung Chung, Carine Bossard, John Duc Nguyen, Emily Creger, Brian W. Eastman, Chi Ching Mak, Maureen Ibanez, Abdullah Ghias, Joseph Cahiwat, Long Do, Shawn Cho, Jackie Nguyen, Vishal Deshmukh, Josh Stewart, Chiao-wen Chen, Charlene Barroga, Luis Dellamary, Sunil K. KC, Timothy J. Phalen, John Hood, Steven Cha, Yusuf Yazici


American Association for Cancer Research (AACR) - Advances in Ovarian Cancer Research | September 13 - 16, 2019
Atlanta, GA

  • SM08502, a novel, small-molecule CDC-like kinase (CLK) inhibitor, demonstrates strong inhibition of the Wnt signaling pathway and antitumor effects in diverse ovarian cancer models
    Abstract - Poster

American Association for Cancer Research (AACR) - Pancreatic Cancer Meeting | September 06 - 09, 2019
Boston, MA

  • SM08502, a novel, small-molecule CDC-like kinase (CLK) inhibitor, downregulates the Wnt signaling pathway and demonstrates antitumor activity in pancreatic cancer cell lines and in vivo xenograft models
    Abstract - Poster
  • SM08502, a novel, small-molecule CDC-like kinase (CLK) inhibitor, demonstrates activity against cancer stem cell (CSC)-enriched pancreatic cancer cells and suppresses stemness in vitro
    Abstract - Poster
  • Inhibition of tumor growth and post-treatment regrowth by SM08502, a novel, small-molecule CDC-like kinase (CLK) inhibitor, in combination with standard of care in pancreatic cancer models
    Abstract - Poster

American Society of Clinical Oncology (ASCO) | May 31 - Jun 04, 2019
Chicago, IL

  • Effects of SM08502, a Novel, Oral, Small-Molecule Inhibitor of Wnt Pathway Signaling, on Gene Expression and Antitumor Activity in Colorectal Cancer (CRC) Models

Royal Society of Medicine's 13th Medical Innovations Summit | September 17, 2016
London, United Kingdom

  • Samumed's Regenerative Medicine Platform

Award Winning

Overview: Oncology – Solid Tumors

Cancer is the second leading cause of death in the United States.1 Some of the most commonly diagnosed malignancies in the U.S. are cancers of the lung, breast, and gastrointestinal tract (colorectal, pancreas, liver, stomach).1,2 Although recent advances in prevention, detection, and treatment have led to a decline in death rates for lung, breast, and colorectal cancers, their prevalence remains high.1 The high mortality associated with these cancers, particularly lung, pancreas and liver, demonstrates the need for more effective treatment options.

The Wnt pathway is a primary physiological regulator and signaling pathway that controls the activity of stem cells. These specialized cells have unique abilities to self-renew and form multiple cell types and tissues.3 Altered expression or activity of various Wnt pathway components through DNA mutations or epigenetic (without gene mutation) changes in stem or normal cells can cause Wnt signaling to be inappropriately activated, resulting in transformation, proliferation, and replicative immortality of cells.3,4  Therefore this pathway, which is normally tightly regulated, can become hijacked in malignant tumors and contribute to cancer development and progression.3-5 As evidence of this, medical research to date has discovered aberrant activation of Wnt signaling in many cancer types. Therefore, targeted modulation of the Wnt pathway with small-molecule drugs offers a potential therapeutic option for the treatment of a broad range of cancers.

Lung cancer is the leading cause of cancer death and the second most diagnosed cancer in both men and women in the United States. Although cigarette smoking is the number one cause of lung cancer, it can also be caused by environmental exposure to substances such as asbestos and radon and occurs more frequently in persons with a family history of lung cancer. Since spiking in the mid-1980s, the incidence rate has been in decline due to a decrease in tobacco smoking.1,2

  • There will be an estimated 228,150 new cases of lung cancer in 2019 in the U.S., equaling 13% of new cancer cases.1,2
  • In 2019, it will be responsible for an estimated 142,670 cancer deaths.1
  • After diagnosis, only 19%% of patients will survive 5 years or more.1
  • Non-small cell lung cancer (NSCLC) accounts for 84% of lung cancer diagnoses.1

Available evidence suggests that increased Wnt signaling plays a role in tumor development, aggressiveness, and treatment resistance in lung cancer. Although genetic mutations in the Wnt pathway are uncommon in non-small cell lung cancer (NSCLC), activated Wnt signaling is present in most NSCLC cell lines and tumor samples, indicating that epigenetic changes are responsible.6 

  • Several components of the Wnt pathway that drive activation may be overexpressed in NSCLC, and loss of expression or activity of various endogenous Wnt pathway inhibitors has frequently been observed in NSCLC cell lines and resected tumors, suggesting that upregulation of Wnt activity can occur in multiple ways.6
  • Treatment-induced inhibition of specific Wnt pathway activators, or restored expression of endogenous inhibitors decreases proliferation and induces cell death in NSCLC cell lines.6
  • NSCLC cells with activated Wnt signaling are resistant to chemotherapy and radiation.6

Breast cancer (female) is the most frequently diagnosed cancer in the U.S., and the second-leading cause of cancer death among women. Although the vast majority of breast cancer cases are not linked to hereditary genetic mutations, women who inherit mutations in the BRCA1 or BRCA2 genes have significantly increased risk of developing breast cancer. Importantly, 80% of women who get breast cancer do not have a family history of the disease. Improvements in early detection and treatment have led to a decline in breast cancer deaths since the peak in 1989.1,2 About 10-20% of breast cancers are found to test negative for estrogen receptors (ER-), progesterone receptors (PR-), and HER2 (HER2-), meaning the cancer is triple-negative. Triple-negative breast cancer does not respond to hormonal therapy (such as tamoxifen or aromatase inhibitors) or therapies that target HER2 receptors (trastuzumab).7

  • There will be an estimated 268,600 new cases of female breast cancer diagnosed in 2019, equaling 30% of total cancer diagnoses in women and 2,670 in men in the U.S.1,2
  • In 2019, it will be responsible for an estimated 42,260 deaths.1
  • After diagnosis, 90% of female patients will survive 5 years or more.1
  • In 2015, there were an estimated 3,418,124 women living with breast cancer in the U.S.2

Several studies have demonstrated evidence of activated Wnt signaling in breast cancer.8

  • Approximately 50% of breast cancer samples show activated Wnt signaling, and this is linked to reduced overall survival.8
  • Wnt signaling pathway components are often overexpressed in breast cancers, and endogenous pathway inhibitors are downregulated.8
  • Animal models of breast cancer showed that Wnt activity was necessary for tumor growth.8

Colorectal cancer is the second leading cause of cancer death in the U.S. among men and women combined and is the third most common cancer in both men and women. Lifestyle-associated risk factors include obesity, physical inactivity, smoking, and diet. A family history of colorectal cancer or polyps also increases risk.1,2

  • There will be an estimated 145,600 new cases diagnosed in 2019, equaling 8% of all new cancer cases.1,2
  • In 2019, it will be responsible for an estimated 51,020 deaths.1
  • In 2015, there were an estimated 1,332,085 people living with colon and rectum cancer in the U.S.2

The association between aberrant Wnt pathway activity and colorectal cancer is well-documented.9,10

  • Genetic alterations in the Wnt signaling pathway have been identified in colorectal carcinoma.10
  • 81% of colorectal tumor samples harbored mutations in the APC tumor suppressor gene alone, which is a key component and regulator of the Wnt signaling pathway.11

Liver cancer incidence has tripled since 1980, and this rate has increased by about 3% per year in recent years. It is 3 times more common in men than women. Risk factors for developing liver cancer in the U.S. are chronic infection with hepatitis B and/or hepatitis C virus, heavy alcohol consumption, obesity, diabetes, and tobacco smoking. Rare genetic disorders also impart risk.1,2

  • There will be an estimated 42,030 new cases of liver cancer in the U.S. in 2019, equaling 2.4% of all cancer diagnoses.1,2
  • In 2019, it will be responsible for 31,780 cancer deaths.1
  • After diagnosis, only 18% of patients will survive for 5 or more years.1
  • Hepatocellular carcinoma (HCC) will be the diagnosis for 75% of new cases.1

Alterations in Wnt pathway genes through mutation or epigenetic changes are common in liver cancers, particularly HCC, which points to dysregulation of Wnt signaling as a contributing factor to cancer development and/or progression.9,12

  • Up to 90% of HCC samples show evidence of Wnt pathway activation, and 54% of HCC cases had specific alterations in the Wnt signaling pathway.12,13
  • Mutations in genes that encode two important Wnt pathway proteins, the downstream activator of Wnt signaling, and a signaling regulator that serves as a tumor suppressor, are commonly found in HCC cell lines and samples.9,13
  • Increased Wnt signaling in HCC may also be due to epigenetic (without gene mutation) silencing of normally occurring Wnt pathway inhibitors, which is frequently found in HCC tumors.9,12

Pancreatic cancer is the fourth leading cause of cancer death in both sexes. Symptoms do not usually appear until the cancer has progressed, which contributes to the high mortality rate. Risk factors include cigarette smoking, obesity, diabetes, excessive alcohol consumption, and family history of pancreatic cancer.1,2

  • There will be an estimated 56,770 new cases of pancreatic cancer in the U.S. in 2019, equaling 3.2% of all cancer diagnoses.1,2
  • In 2019, it will be responsible for an estimated 45,750 deaths or 7.5% of all cancer deaths.1
  • After diagnosis, only 9% of patients will survive 5 years or more.1

Substantial evidence demonstrates involvement of activated Wnt signaling in pancreatic cancer.14

  • Aberrant Wnt pathway activation is seen in 65% of advanced pancreatic adenocarcinomas.14
  • Analysis of circulating pancreatic cancer cells revealed increased Wnt signaling in these cells, which may contribute to metastasis.15
  • Genome-wide analysis of pancreatic tumors revealed that Wnt pathway genes often carry mutations or are epigenetically altered.16

Stomach cancer is the 15th most commonly diagnosed cancer by site in the U.S. Men are nearly twice as likely as women to develop stomach cancer. Other risk factors include obesity, heavy alcohol consumption, and infection with Heliobacter pylori (H. pylori).1,2

  • There will be an estimated 27,510 new cases of stomach cancer in the U.S. in 2019, equaling 1.5% of all cancer diagnoses.1,2
  • In 2019, it will be responsible for an estimated 11,140 deaths (1.8% of all cancer deaths).1
  • After diagnosis, 31% of patients will survive 5 years or more.1

Evidence of aberrant activation of the Wnt signaling pathway has been demonstrated in stomach cancer and may be involved in disease development and progression.17

  • Activated Wnt signaling has been found in more than 30% of gastric cancers.17
  • Mutations in key genes of the Wnt pathway may be driver mutations (i.e., early mutations that initiate cancer development) in gastric cancers.17

Preclinical studies show that H. pylori may cause stomach cancer through interactions with the Wnt pathway.17


    1. American Cancer Society. Cancer Facts &Figures 2019. Atlanta: American Cancer Society; 2019.
    2. Noone AM, Howlader N, Krapcho M, Miller D, Brest A, Yu M, Ruhl J, Tatalovich Z, Mariotto A, Lewis DR, Chen HS, Feuer EJ, Cronin KA (eds). SEER Cancer Statistics Review, 1975-2015, National Cancer Institute. Bethesda, MD,, based on November 2017 SEER data submission, posted to the SEER web site, April 2018.
    3. Clevers H & Nusse R. Wnt/β-catenin signaling and disease. Cell. 2012;149(8):1192-1205.
    4. Hanahan D & Weinberg R. Hallmarks of cancer: the next generation. Cell. 2011;144(5):646-7.
    5. de Sousa EM, Vermeulen L, Richel D, Medema JP. Targeting Wnt signaling in colon cancer stem cells. Clin Cancer Res. 2011;17(4):647-53.
    6. Stewart DJ. Wnt signaling pathway in non-small cell lung cancer. J Natl Cancer Inst. 2014;106(1):djt35.
    7. Accessed September 19, 2017.
    8. Lin SY, Xia W, Wang JC, et al. Beta-catenin, a novel prognostic marker for breast cancer: its roles in cyclin D1 expression and cancer progression. Proc Natl Acad Sci USA. 2000;97: 4262–6.
    9. Polakis P. Wnt signaling in cancer. Cold Spring Harb Perspect Biol. 2012;4(5):a008052.
    10. Zhan T, Rindtorff N, Boutros M. Wnt signaling in cancer. Oncogene. 2017;36:1461-73.
    11. The Cancer Genome Atlas Network. Comprehensive molecular characterization of human colon and rectal cancer. Nature. 2012;487(July19):330-7. 
    12. Thompson MD & Monga SPS. Wnt/β-catenin signaling in liver health and disease. Hepatology. 2007;45:1298-1305.
    13. Schulze K, Imbeaud S, Letouze E, et al. Exome sequencing of hepatocellular carcinomas identifies new mutational signatures and potential therapeutic targets. Nat Genet. 2015;47(5):505-11.
    14. Zeng G, Germinaro M, Micsenyi A, et al. Aberrant Wnt/beta-catenin signaling in pancreatic adenocarcinoma. Neoplasia. 2006;8(4):279-89.
    15. Yu M, Ting DT, Stott SL, et al. RNA sequencing of pancreatic circulating tumour cells implicates WNT signalling in metastasis. Nature. 2012;487(7408):510-3.
    16. Sahin B, Iacobuzio-Donahue, O’Reilly EM. Molecular signature of pancreatic adenocarcinoma: an insight from genotype to phenotype and challenges for targeted therapy. Expert Opin Ther Targets. 2016;20:341-59.
    17. Chiurillo MA. Role of the Wnt/β-catenin pathway in gastric cancer: an in-depth literature review. World J Exp Med. 2015;5(2):84-102.